Oncology

At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, Sriram Shankar, senior consultant, INC Strategy Consulting, shared his thoughts on the implications of value frameworks for payer strategy.

When undergoing therapy for cancer, patients must be aware of the risks of adverse interactions between the therapy and any other drugs or herbal supplements they take, a new study cautions.

According to a research study published in the journal Cancer, Asian women are less likely than non-Hispanic white women to receive timely follow-up after an abnormal screening mammogram.

A new report from the United States Government Accountability Office is calling for pharmacy systems to better serve veterans through additional capabilities for viewing, exchanging, and using data.

A collaborative study among scientists working across 3 continents has found a strong association between circulating free DNA in patients being treated with olaparib (Lynparza) for prostate cancer and disease outcome.

Young adult cancer survivors face an uncertain path to parenthood-here is one story.

The European Commission has approved Rixathon, a biosimilar of the cancer drug rituximab, for use in Europe, according to an announcement from Novartis, whose Sandoz division manufactures the biosimilar.

Scott Ramsey, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses determining cost effectiveness of novel treatments, such as immuno-oncology agents, and potential solutions to reducing financial toxicity in cancer care.

Staff at mental health hospitals have long believed that tobacco helped calm patients, when in fact the nicotine only covered symptoms of withdrawal.

At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, pharmaceutical developers shared strategies on how a “value” culture can be infused right from the preclinical stage of oncology product development.

As cancer care moves to payment focused on improving value, payers are more often using regulation and incentive to improve the integration of palliative care into oncology practice.

Guidelines recommend against screening for cancer in patients with shortened life expectancy, but a recent study revealed older patients may not want to consider their life expectancy when discussing with a clinician whether they should stop undergoing cancer screening.

Amy Byer Shainman narrates how the knowledge that she was BRCA1 positive led to her decision to undergo prophylactic surgery.

This article provides insight on the work of 7 of Project ECHO’s replicating partners from around the world who are implementing the ECHO model to address the knowledge gap that underlies integrated palliative care crisis.

A meta-analysis spearheaded by The International Testicular Cancer Consortium has identified new susceptibility loci in the human genome that can increase a person’s risk of developing inherited testicular germ cell tumors.

An update on the latest developments in clinical and healthcare services research in oncology.

AJMCtv® interviews let you catch up with experts on what’s new and important about changes in healthcare. The interviews provide insights from key decision makers-from the clinician to the health plan leader to the regulator. When every minute in your day matters, AJMCtv® interviews keep you informed. You can access the video clips at www.ajmc.com/interviews.

The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.

High-quality cancer care can only occur when the “transitions in care” are delivered in a prospectively planning, systematic, patient-centered way.

Pharmacists play an integral role in enhancing transitions of care in patients undergoing cancer treatment through medication reconciliation, education, and post-discharge follow-up to ensure optimal, safe, and effective medication use.

As the American healthcare sector transitions towards value-based and patient-centered care models, New York Oncology Hematology has seen success in modernizing palliative care delivery, integrating social services with the overall care experience, and using the family meeting model to ensure families remain involved throughout the patient’s treatment process.

A rundown of sessions at The Community Oncology Alliance (COA) annual meeting, held April 27-28, 2017, near Washington DC. This year’s theme was Fueling the Cancer Moonshot.

A roundup of the panels and sessions at the National Comprehensive Cancer Network's 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, held March 23-25, 2017, Oralndo, Florida.

The American Medical Association (AMA) has announced its choice of Barbara McAneny, MD, to lead as president-elect, making her the first oncologist to take the reins of the nation’s largest physician organization.

Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.